and may present novel opportunities for
therapeutic intervention. This review aims to provide a
and significant long-term disabilities among survivors, underscoring the urgent need for innovative
therapeuticBeylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) . Emphasis is placed on the role of the BBB and BTB in modulating drug delivery and
therapeutic outcomes
with potential
therapeutic effects. Results: A total of 325 upregulated genes and 103 downregulated genes
their potential as
therapeutic targets for CVD. Special emphasis is placed on miRNAs that regulate T cells
Gao, Xin,
Huang, Yanming,
Wei, Tonghui,
Xue, Jingmin,
Iurii, Filippov,
Yang, Laishou,
Wang, Liying,
Li, Hao,
Mo, Genshen,
Huang, Yuze,
Xie, Haonan,
Wang, Hang,
Lou, Shenghan,
Han, Peng (2025) progression and chemoresistance, highlighting potential
therapeutic targets for improving treatment outcomes
Fedorova, Yu. Yu.,
Aminova, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Romanova, A.R.,
Nurgalieva, A.Kh.,
Andreeva, E.A.,
Darvish, M.,
Khusnutdinova, E.K.,
Prokofyeva, D.S. (2025) as
therapeutic pathomorphosis, not identify statistically significant differences in the methylation levels